SEC Tracker
Get the app

Onconetix ONCO

Onconetix to hold annual meeting on Nov 10

Proxy statement

Form
DEF 14A
Filed
Importance
Routine
  1. Annual meeting on Nov 10, 2026 at 9:00 a.m. Eastern Time.
  2. Re-elect Josh Epstein as Class II director for 3-year term.
  3. Approve issuance of up to 154,856,150 shares of Common Stock upon conversion of Series F Preferred Stock.
  4. Grant Board authority to effect reverse stock split at 1-for-2 to 1-for-15 ratio.

Written from the DEF 14A on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Onconetix files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Enveric Biosciences ENVB public float $4M, Jun 30, 2025
  2. Polomar Health Services PMHS public float $4M, Jun 30, 2025
  3. Q/C Technologies QCLS public float $4M, Jun 30, 2025
  4. Integrated Biopharma INBP public float $3M, Dec 31, 2025
  5. Jaguar Health JAGX public float $4M, Jun 30, 2025